Richard J. Stopforth
Southampton General Hospital
7 Papers
Richard J. Stopforth is an academic researcher from Southampton General Hospital. The author has contributed to research in topics: Tumor microenvironment & Immunotherapy. The author has an hindex of 5, co-authored 5 publications. Previous affiliations of Richard J. Stopforth include University of Southampton.
Chat about Author
Papers
Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?
TL;DR: Current and future developments relating to enhanced effector function, such as the ability to form multimers on the target cell surface, are discussed, chiefly involving the combination of anti-CD20 mAbs with various other agents to resensitize patients to treatment.
New revelations from an old receptor: Immunoregulatory functions of the inhibitory Fc gamma receptor, FcγRIIB (CD32B).
TL;DR: An overview of the established and noncanonical functions of FcγRIIB is presented and how this knowledge might be exploited therapeutically is discussed.
28
Shaving Is an Epiphenomenon of Type I and II Anti-CD20-Mediated Phagocytosis, whereas Antigenic Modulation Limits Type I Monoclonal Antibody Efficacy.
Lekh N. Dahal,Chie Yin Huang,Richard J. Stopforth,Abbie Mead,Keith W. Chan,Juliet X. Bowater,Martin C. Taylor,Priyanka Narang,H.T. Claude Chan,Jinny H. Kim,Andrew T M Vaughan,Francesco Forconi,Stephen A. Beers +12 more
TL;DR: Under all conditions tested, modulation predominated in rituximab loss, whereas shaving represented an epiphenomenon to phagocytosis, suggesting that shaving may represent an important mechanism of resistance when modulation is curtailed, and glycoengineering mAb to increase affinity for FcγR may enhance resistance because of shaving.
21
Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB.
TL;DR: How an understanding of the biology of the inhibitory Fc receptor, FcγRIIB (CD32B), is leading to the development of improved mAb treatments is reviewed.
HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy
Khiyam Hussain,Rena Liu,Rosanna C.G. Smith,Kristin Müller,Mohammadmersad Ghorbani,Sofia A. Macari,Kirstie L. S. Cleary,Robert J. Oldham,Russell B. Foxall,Sonya James,Steven G. Booth,Tom D Murray,Lekh N. Dahal,Chantal E. Hargreaves,Robert S. Kemp,Jemma Longley,James Douglas,Hannah Markham,Serena J Chee,Richard J. Stopforth,Ali Roghanian,Matthew J. Carter,Christian H. Ottensmeier,Björn Frendéus,Ramsey I. Cutress,Ruth R. French,Martin J. Glennie,Jonathan C. Strefford,Stephen M. Thirdborough,Stephen A. Beers,Mark S. Cragg +30 more
TL;DR: In this paper , the effects of hypoxia inducible factor (HIF) activation on mAb mediated depletion of human and murine cancer cells were assessed using a multi-OMIC approach coupled with in vitro functional assays and in vitro tumor models.